Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com
A00308 | Pages: 506 | Charts: 67 | Tables: 180 |
The global nebulizer market size was valued at $1.1 billion in 2022, and is projected to reach $2.3 billion by 2032, growing at a CAGR of 7.8% from 2023 to 2032. Nebulizers are used in treatment of chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, cystic fibrosis, pulmonary fibrosis, and others. Thus, rise in prevalence of chronic respiratory diseases is anticipated to drive the demand for nebulizer and boost the growth of the market. For instance, according to American Lung Association, it was reported that, chronic obstructive pulmonary disease affects 12.5 million adults in U.S. and accounts for millions of emergency department visits and tens of billions in healthcare costs each year. Thus, rise in prevalence of COPD drives the demand for nebulizers and fuels the market growth.
[COVIDIMPACTSTATEMENT]
Key Takeaways:
A nebulizer is a medical device used to convert liquid medication into a fine mist or aerosol, allowing patients to inhale the medication into their respiratory system. Nebulizers are primarily used to deliver respiratory medications to individuals with various lung conditions, such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, and other respiratory disorders. Nebulization is an effective method for delivering medication directly to the airways, providing quick relief and managing chronic respiratory symptoms.
Market Dynamics
The nebulizer market is driven by increase in prevalence of asthma, rise in geriatric population and presence of large market players who manufacture nebulizers. Nebulizers are commonly used in the treatment of asthma to deliver medication directly into the airways, helping to relieve and manage asthma symptoms. Nebulizers convert liquid asthma medications into a fine mist or aerosol that can be inhaled into the lungs. This allows the medication to reach deep into the airways, providing quick and effective relief. Thus, rise in prevalence of asthma is anticipated to boost the growth of the market. For instance, according to American College of Allergy, Asthma, and Immunology, it was reported that, 8.3% of Americans have asthma. Of these 26.5 million, 20.4 million are adults and 6.1 million are children. Thus, rise in prevalence of respiratory diseases will be anticipated to fuel the demand for nebulizer and boost the growth of market.
Moreover, geriatric population is more susceptible to respiratory diseases such as asthma. Thus, rise in geriatric populations is anticipated to increase in prevalence of respiratory diseases. Therefore, this factor is anticipated to fuel the demand for nebulizer and fuels the growth of the market. For instance, according to United Health Foundation, America’s Health Rankings, it was reported that, more than 55.8 million adults ages 65 and older live in the U.S., accounting for about 16.8% of the nation’s population. By 2040, that proportion is projected to grow to 22%. Moreover, according to Asthma and Allergy Foundation of America, it was reported that asthma is common in adults ages 65 and older. Around 7.8% of older adults in the U.S. have asthma. Thus, there is increase in demand for nebulizers, with rise in prevalence of asthma in geriatric population. This is expected to witness growth during the forecast period.
In addition, advantages associated with nebulizers such as it being cost effective, easy to use, effective in delivering drugs and others are anticipated to fuel the demand for nebulizer devices and boost the market growth. Moreover, large presence of market players who manufacture nebulizers is expected to boost the growth of the market. For instance, Omron Healthcare Inc., Koninklijke Philips N.V., PARI Respiratory Equipment, Inc., and Rossmax International Ltd. are some major market players who manufacture nebulizers.
On the other hand, unawareness regarding use of nebulizer and maintenance of hygiene of accessories of device at homecare setting is a major restraining factor for the growth of the market. For instance, in October 2021, according to report shared by National Library of Medicine, use of nebulizer at home was a challenge at all stages including setting up and operating nebulizer, filling up of medication, inhalation technique, end point dismantling, and maintenance. The main challenge experienced by the participants was with cleaning and disinfecting of nebulizer. Therefore, this factor is anticipated to hinder the growth of the market during the forecast period.
Segmental Overview
The nebulizer market is segmented into product, type, application, portability, end user, and region. By type, the market is classified into jet nebulizer, ultrasonic nebulizer, and mesh nebulizer. By product, the market is classified into equipment and accessories. By application, the market is classified into COPD, asthma, and others. By potability, the market is bifurcated into tabletop and portable. By end user, the market is divided into hospitals, clinics, and homecare setting.
Region-wise, the nebulizer industry is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
By Type
The market is classified into jet nebulizer, ultrasonic nebulizer, and mesh nebulizer. The jet nebulizer segment is expected to be the fastest growing segment during the forecast period owing to advantages associated with jet nebulizer and cost effectiveness of jet nebulizer.
[TYPEGRAPH]
By Product
The market is classified into equipment and accessories. The accessories segment is expected to be the fastest growing segment during the forecast period owing rise in use of nebulizers in homecare setting and increase in awareness among population regarding usage of nebulizers.
[PRODUCTGRAPH]
By Application
The market is classified into COPD, asthma and others. The COPD segment is expected to be the fastest growing segment during the forecast period owing rise in usage of nebulization treatment in COPD and provision of advance nebulizers by market players for COPD treatment
[APPLICATIONGRAPH]
By Potability
The market is segmented into tabletop and portable. The tabletop segment dominated the market in 2022 and is expected to remain dominant during the forecast period, owing to cost effectiveness of tabletop nebulizer and increase in populations suffering from respiratory chronic diseases.
[PORTABILITYGRAPH]
By End User
The market is divided into hospitals, clinics, and homecare setting. The hospital segment dominated the market in 2022 and is expected to remain dominant during the forecast period, owing to increase in populations suffering from chronic respiratory diseases and rise in populations taking admission in hospital for treatment of respiratory diseases.
[ENDUSERGRAPH]
By Region
The North America nebulizer market is expected to contribute large market share, owing to the presence of large market players who manufacture nebulizers and rise in populations suffering from chronic respiratory diseases. For instance, DeVilbiss Healthcare LLC, GF HEALTH PRODUCTS, INC., Trudell Medical International, Allied Healthcare Products Inc., and Teleflex Medical Inc are major market players who manufacture advanced nebulizers such as ultrasonic and mesh nebulizers.
In addition, nebulizers are common device used in the treatment of respiratory disease such as asthma. Thus, rise in population suffering asthma is anticipated to fuel the demand for nebulizer and boost the growth of market. For instance, according to report shared by Asthma and Allergy Foundation of America, in April 2022, nearly 26 million people in the U.S. have asthma. This equals about 1 in 13 people. Nearly 21 million U.S. adults ages 18 and older have asthma. Moreover, chronic obstructive pulmonary disease (COPD) is a major health issue in Canada, with a significant portion of the population affected by the disease. According to the Lung Association, an estimated 3 Mn Canadians are living with COPD, and the disease is responsible for approximately 10% of all deaths in the country. This growing prevalence of COPD is expected to drive the demand for COPD therapeutics in Canada.
Thus, rise in number population suffering from respiratory chronic disease anticipated to drive the demand for nebulizers and large presence of market players who manufactures nebulizers is anticipated to boost the growth of market.
However, the Asia-Pacific nebulizer market forecast is expected to grow, owing to rise in populations suffering from chronic respiratory diseases such as chronic obstructive pulmonary diseases, cystic fibrosis, asthma, and others and increase in geriatric populations. For instance, according to International Primary Care of Respiratory Group (IPCRG), it was reported that, India contributes to 15.69% of global chronic respiratory diseases but 30.28% of all global deaths due to chronic respiratory disease occur in India. India has the highest number of COPD (Chronic Obstructive Pulmonary Disease) cases in the world. Thus, this factor is anticipated to boost the need for nebulizer for treatment of diseases and expected to drive the growth of nebulizer market in Asia.
In addition, geriatric population is more susceptible to chronic respiratory diseases. Thus, rise in geriatric populations is anticipated to increase in prevalence of respiratory diseases. Therefore, this factor is anticipated to fuel the demand for nebulizers and boost the growth of market. For instance, according to Economic and Social Commission for Asia and the Pacific (ESCAP), in 2022, one in seven people are aged 60 years or older in Asia and the Pacific. By 2050, one in four people are projected to belong to this age group. Thus, the share and the number of older persons in the region is growing very fast and compared to other world regions.
[REGIONGRAPH]
Competition Analysis
Some of the major companies that operate in the global nebulizer industry include OMRON Healthcare, Inc, Koninklijke Philips N.V., DeVilbiss Healthcare LLC., GF Health Products, Inc., Trudell Medical International Inc., Allied Healthcare Products, Inc., Teleflex Incorporated, Vyaire Medical, Inc., PARI Respiratory Equipment Inc., and Rossmax International Ltd.
Recent Product Launch in the Nebulizer Market
In March 2021, PARI Pharma GmbH, a company focused on advanced aerosol delivery systems based on eFlow Technology, announces the authorization of the LAMIRA Nebulizer System for delivery of Insmed’s drug product ARIKAYCE (amikacin liposome inhalation suspension) in Japan.
Key Market Segments
Key Market Players